
News|Articles|October 1, 2009
FDA Pipeline preview, October 2009 (doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, quinazoline495)
Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Drug Pricing Not Main Driver of State Medicaid Spending | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025
4
Generalized Anxiety Disorder Affects More Than One in Ten U.S. Adults | AMCP Nexus 2025
5


















































